Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Standards of Care II01:19

Standards of Care II

1.2K
Nurses bear specific legal responsibilities under several federal statutes, including:
1.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Standards of Care I01:22

Standards of Care I

1.3K
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
1.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sample Size Determination for Decision-centered Pragmatic Trials.

Journal of clinical epidemiology·2026
Same author

Linking Minimally Important Differences (MID) and Acceptable Regret to Elicit Values and Preferences in Health Decision Models.

Journal of evaluation in clinical practice·2026
Same author

Brexucabtagene Autoleucel in the Outpatient Setting: A Single-Institution Experience.

Transplantation and cellular therapy·2026
Same author

Is Pseudo-progression post-CAR T therapy real?

Clinical hematology international·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Airway mucus in infection.

Frontiers in physiology·2026

Related Experiment Video

Updated: Mar 30, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Kenneth C Anderson, Melissa Alsina, Djordje Atanackovic

    Journal of the National Comprehensive Cancer Network : JNCCN
    |November 11, 2015
    PubMed
    Summary

    Multiple myeloma (MM) is a cancer of plasma cells that is increasing in incidence. This issue addresses the NCCN Clinical Practice Guidelines for managing solitary plasmacytoma and newly diagnosed MM.

    More Related Videos

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    13.6K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    9.2K

    Related Experiment Videos

    Last Updated: Mar 30, 2026

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    7.3K
    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    13.6K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    9.2K

    Area of Science:

    • Oncology
    • Hematology

    Background:

    • Multiple myeloma (MM) is a malignant plasma cell neoplasm.
    • MM leads to bone destruction and marrow failure.
    • The incidence of MM is increasing, according to the American Cancer Society.

    Purpose of the Study:

    • To present the NCCN Clinical Practice Guidelines for Oncology.
    • To address the management of solitary plasmacytoma.
    • To provide guidance for newly diagnosed multiple myeloma.

    Main Methods:

    • Review of current clinical practice guidelines.
    • Synthesis of evidence-based recommendations.
    • Expert consensus on management strategies.

    Main Results:

    • Guidelines for solitary plasmacytoma management are detailed.
    • Recommendations for newly diagnosed MM are outlined.
    • Focus on optimal patient care pathways.

    Conclusions:

    • Adherence to NCCN Guidelines is crucial for MM patient outcomes.
    • Standardized management improves treatment efficacy.
    • Ongoing updates ensure evidence-based care for MM and related disorders.